Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
9.45
-0.09 (-0.94%)
Nov 13, 2026, 4:00 PM EST - Market closed
← View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 10, 2026

Summary

Revuforj and Niktimvo are growing, with transplant, maintenance and earlier-line use supporting expansion. Key catalysts include frontline and combination data in 2027, a Niktimvo pivotal readout in early 2028, and new pipeline programs.

Paul Jeng
Analyst, Guggenheim

Welcome to this next session. My name is Paul Jeng. I am a biotech analyst. Company is Syndax, and I am with Nick Botwood, CMO.

Nicholas Botwood
CMO, Syndax Pharmaceuticals

Good with you.

Paul Jeng
Analyst, Guggenheim

Great. Maybe a good place to start is for those that might be newer to the story, could you provide a quick overview of Syndax and your two launch medicines, Revuforj and Niktimvo, as well as the main value drivers for the next few years?

Michael Metzger
CEO, Syndax Pharmaceuticals

Yeah. Thanks so much. Sure. Syndax is a fully integrated commercial and R&D company. We are now commercializing two agents, Niktimvo and Revuforj. Revuforj is for acute AML and ALL, specifically two subtypes, KMT2A acute leukemia and NPM1 mutant leukemia. We are indicated for both adults and pediatrics in those populations, and we were the first to pioneer a new class of medicines called the menin class. We are now the leader in that category and continuing on our leadership as we have launched that product, as we are about in our second year of launch now. We recently had our quarterly results. Product is continuing to grow very nicely, and we are continuing with our dominant position across all the segments.

That product, we are continuing also to advance into additional trials and move it into the frontline setting, which is a multi-billion dollar category, and we are very excited about what comes next for Revuforj. Then I will say for Niktimvo, it is very similar in the sense that we launched the product in 2025. Now we are in our second year. Product is doing very, very well, growing quarter-to-quarter. Like Revuforj, we are growing new patient starts. We are also growing revenue. The last quarter showed growth for Niktimvo of revenue growth of 12%. Revuforj grew 11%. Then, of course, we are now advancing both products to frontline indications. Niktimvo will have some data in the first quarter of next year, really looking at newly diagnosed populations, and then a pivotal trial in early 2028. Both are expanding franchises. Both have a really nice leadership position for us.

We continue on building the rest of the company as well, so it is not just commercial products, which are exciting, but also we have a pipeline now which we have started to talk about. One is a mutant selective EGFR inhibitor. It is an allosteric, the first of its kind to go into the clinic. We will file that IND at the end of this year and then start clinical trials next year. So exciting new wave of science for us as we pioneer a new mechanism. Then, of course, there is a next generation menin inhibitor for myelofibrosis, which we presented data at ASH last year, and then we published some data this year indicating the mechanism should be active in that disease as well. So that is a whole new area of science for us in myelofibrosis, which we are excited about.

We should have some data with Revuforj in that category, and then also follow on with the IND in 2027. So lots of important milestones. I know you asked and where we are going. I think we could see that we will continue to build our position with Revuforj and Niktimvo, and so that is commercial performance, but it is also clinical performance, as well as the new pipeline, which is emerging quickly.

Paul Jeng
Analyst, Guggenheim

Okay, fantastic. So maybe starting with the commercial front, and as you mentioned, you just had earnings for Revuforj, roughly $61 million. So I guess what are the key drivers at this point in the launch curve, and two years in, is it more new patient starts? Is it longer time on treatment, or are there some other factors at play?

Michael Metzger
CEO, Syndax Pharmaceuticals

Well, it is certainly both, right? I think we, as I mentioned, we have sort of the dominant position in new patient starts. If you look across the entire category of age, you can see that we have new patients entering every month and growing every month. So we feel quite good about new patient starts. If you look at from a revenue perspective, 80%+ of the revenue for the category in relapsed refractory disease. So that just tells you how vast the opportunity is for us and how we will continue to build on that leadership position.

But when it comes to how the business grows, it is not only new patient starts, it is also recurring revenue, it is also patients staying on therapy for longer, driven by the fact that we treat patients earlier and earlier in the relapse refractory setting, which gets them to a higher rate of response. Then you can take them to transplant in higher numbers, which we are seeing quarter- to- quarter as that builds, and then bringing them back and physicians putting them on for maintenance, which adds a whole another dimension of growth to how Revuforj will continue.

So you have this new patient start, of course, is important, but bringing patients back for maintenance, which is up this quarter from last quarter, not only for KMT2A, which is now at about 60% of the patients coming back for maintenance that have gone to transplant, but you are seeing NPM1 patients increasingly go to transplant and also come back for maintenance. That is 50% this quarter. So I think that aspect of our business is an enduring piece and a differentiator for us as we get into even earlier lines where we are going to see hopefully patients staying on therapy for months, if not years.

Paul Jeng
Analyst, Guggenheim

Okay. Yeah, I know the sort of getting to transplant and then maintenance dynamic is a big part of the Revuforj story. So I am just curious about how you think about where the trajectory can land in terms of like how many patients could you actually be getting into transplant for the respective KMT2A and NPM1 settings, and then sort of how many of them could you get onto maintenance as sort of a peak opportunity?

Michael Metzger
CEO, Syndax Pharmaceuticals

I have to say it's very encouraging. I think what we've seen in this and what we've been able to do with Revuforj, and physicians were very eager when they first saw the data with KMT2A to get these patients through transplants. The only chance you have for an enduring cure for a patient with acute AML, and the ability for Revuforj to do that is unique. Getting them to transplant now, KMT2A at about 50% of the patients getting to transplant and about 60% coming back. I would expect that we could increase the number of patients going to transplant, maybe get to 60% for KMT2A, maybe get to 70%-80% of the patients coming back for maintenance.

What's the big surprise this quarter is that we've looked back at the data, and we're starting to see this phenomenon where even NPM1 patients who are historically a little bit older, less able to necessarily have a transplant, we're actually seeing them go to transplant. So now, this quarter, we saw about 40% of the patients going to transplant and about 50% of those coming back for maintenance. Excellent sign that physicians are actually really pushing this. They really want to get patients onto transplant and then back to maintenance. So that could probably go for NPM1. I would expect we would increase the transplant rate a bit more, and maybe a bit more on the patients returning, so maybe 60%, 70% of the patients returning that are NPM1 for maintenance.

Again, all very positive forward indicators of where the business is going and what Revuforj can specifically do as a leader in the class.

Paul Jeng
Analyst, Guggenheim

Okay. How is that all netting out to your current view on the treatment duration for patients who are either transplanted versus not transplanted?

Michael Metzger
CEO, Syndax Pharmaceuticals

Yeah, also very encouraging. I think, historically, AML is unfortunately a very short duration treatment for many of these agents. For us, what we're seeing and specifically calling out patients who receive Revuforj, receive a response, and then stay on medicine, it's in the order of seven months or so, what we're seeing today. That's an evolving number, right? It'll continue to grow, we believe, but that's very encouraging. Those are patients that are not getting a transplant, but they're getting to response. When you look at it from the perspective of patients who are going on to maintenance, that cohort of patients is out over nine months. We expect that to continue. The reason we expect it to continue to grow is what physicians tell us. They would like to do maybe a year to two years on average maintenance for patients.

Some physicians are even telling us most recently that they don't want to take them off drug because they're tolerating it really well. It's the drug that got them to a response, and these patients are fragile. Keep them on as long as possible. So that could exceed the one to two-year mark that people tell us that they want to employ. Again, very encouraging that that's the dynamic that we're driving.

Paul Jeng
Analyst, Guggenheim

Okay. Then obviously, a much larger driver of longer-term revenue would be label expansion and moving into the earlier line setting.

Michael Metzger
CEO, Syndax Pharmaceuticals

Yes.

Paul Jeng
Analyst, Guggenheim

I guess first, can you update us on the sort of status of those two first-line trials, EVOLVE-2 and REVEAL, and how enrollment is going against plan?

Michael Metzger
CEO, Syndax Pharmaceuticals

Yeah. We haven't given specific guidance on where we are. I think we're encouraged by our progress there. We have two large trials, as you mentioned, EVOLVE and REVEAL. One is REVEAL is in the fit setting, combining with chemotherapy, 7+3, and in the unfit setting with VEN-AZA. We'll talk about some of the stuff we'll have at ASH this year, but lots of data updating on those patient populations and the phase I/II studies that we're running there in support of what we expect to see in those trials. I think that's also very important to how physicians see those trials and enrolling those trials. We're encouraged by not only the data, but the fact that we now have hundreds of sites opened, and we're tracking.

More to say probably in 2027 about that, and obviously, it's a competitive space, so we're not necessarily revealing too much, but we feel good at this time where we are.

Paul Jeng
Analyst, Guggenheim

Okay. Then, yeah, maybe on ASH, as you bring up, a large presence will be there for your company. Maybe just help us parse out what the major highlights will be and sort of what the focus area is for the data that you have there.

Michael Metzger
CEO, Syndax Pharmaceuticals

Yeah, maybe, Nick, do you want to talk about ASH?

Nicholas Botwood
CMO, Syndax Pharmaceuticals

Thank you, Paul. Thank you for the question. Thank you for having us. Nice to be here. ASH is always a focus for us. It is the biggest hematology conference in the world. We focus on it, prepare for it, and we will show up with a very dominant presence this year, which I think really highlights our scientific leadership in the menin space. We had 14 abstracts accepted this year. Very proud now to be able to talk about that. Now the ASH abstracts are out. We have had seven of those accepted as oral presentations. Just as a point of reference, that is actually more than all of the rest of the menin field put together, which I think speaks to our history of pioneering in the menin space since we had our first approvals and first delivered the AUGMENT data.

There is a lot of data to talk about, and it is important data. The reason I say that is because the treatment of leukemia is very nuanced and somewhat complex. There are many facets to it. There is treatment in combination. There is treatment in earlier lines of therapy. There are treatments of subtypes of patients, specifically subtypes like NPM1, NUP98 or ALL or pediatric populations. Maintenance is increasingly becoming a focus, and we will present, either in oral or poster, data across the entire spectrum of AML, and this is what physicians want to see. This is how you secure confidence in the treatment of patients. You present data that allows informed decision-making as it relates to subtypes of acute leukemia, as it relates to maintenance, as it relates to combinations. We are very excited to have such a strong presence at ASH.

I would maybe highlight a few areas to home in on. Firstly, obviously, a big focus on newly diagnosed patients. We will have three data sets of combinations with standards of care in frontline on newly diagnosed patients with AML. Perhaps most significantly, an update to our BEAT AML data from Josh Zeid at UNC. We presented these data previously, but with a much shorter median follow-up. When we get to the congress in an oral, we will present a much larger cohort of patients with longer follow-up. I think there are three things to take from that data set. Number one is it continues to be very tolerable to combine with VEN-AZA at standard doses. Number two is if you look at the complete response rate, it remains very high at 68%, which is a step change above what you would expect from VEN-AZA alone from historical controls.

The third and most significant thing is the survival, because ultimately, survival is the gold standard in these sorts of studies. The median overall survival in the all-treated population, which includes KMT2A and NPM1, is 24 months. If you look at the subset of patients of NPM1, which is most relevant to our pivotal phase III, the median is not reached yet, and actually, the percentage of patients alive at two years is 56%. What that means is we are anticipating the median for those NPM1 patients will be in excess of two years, which is incredibly exciting. Those are going to be very important data in the frontline combination. I would then highlight two areas. One is the ability of revumenib to get patients to transplant, and we will have a data set looking at that.

The important thing about that is it's not just patients that get CR/CRh that gets to transplant. 40% of the patients from our AUGMENT series that went on to get a stem cell transplant didn't have a CR/CRh, so that would include other types of morphological remission, including MLFS. That's actually very exciting, because whilst everybody's focused on CR/CRh, it's actually a regulatory endpoint, and what we've shown with revumenib is it drives response rates more generally and gives patients the best chance of getting to maintenance and transplant. Then we'll have a very important data set from Dr. Brian Ball, City of Hope, which is the largest transplant center in the U.S.

It's the first formal phase I done of a menin inhibitor actually looking at maintenance, and that will show it's very tolerable and feasible and that we have patients with good MRD clearance all the way out to one and even beyond one year, out to two years in some cases. In fact, we heard personally from Dr. Ball, I was talking with him the other week, that some of his patients, even at two years, who are doing well and tolerating the drug well, want to continue on therapy beyond two years, and that's very exciting for patients that they're still in this durable remission with such a difficult disease. Then third and last area, we'll be the only company, again, that presents real-world series.

We're very proud of these data because it actually shows how revumenib is getting used in the real-world setting, and from two leading centers, some data from Moffitt and then some data under the umbrella of the ROAR study. It's called the ROAR, and this is Dana-Farber and Memorial Sloan Kettering. The reason those data are particularly relevant, I think, is because unlike our AUGMENT series, which was done three years ago, the real-world data, I think, are much more comparable to some of the more recent menin-reported data, because we have led a complete transformation of the treatment of AML. The way patients get treated now is completely different from how the patients get treated when we were pioneering the space three, four years ago. If you compare our real-world data with some of the more recently reported menin series, it's actually extremely comparable and competitive.

If you look at the overall response rate, if you look at the CR/CRh to monotherapy, if you look at outcomes in combination, the results are really quite compelling. The combination piece is important because we know that revumenib is extremely well-tolerated in combination. It has a short half-life, it's dosed twice a day, it allows for a lot of flexibility in dosing. Some of the more recent menin reports, which are admittedly highly potent molecules, have high incidences of cytopenias. We know now, because of the pioneering work we did with John Crispino, that actually cytopenias are an on-target effect of menin inhibition. If you see high cases of neutropenia, thrombocytopenia, that can be a challenge, particularly if you want to combine.

Now, unfortunately, we're not going to see any combination data at ASH, it would seem, because I think it would be important to see how that's tolerated. But that is something I would watch for because it is increasingly becoming a standard approach to treating patients to treat in combination with standards of care. We're very excited about ASH. We think we're really going to have a leading presence, as you'd expect, as leaders of the menin space.

Paul Jeng
Analyst, Guggenheim

Great. Thanks for all that color. Really helpful to orient ahead of the conference. Just your comment on combinations, I thought I wanted to follow up on. I guess my question is, are you seeing any use of combinations off-label currently in the commercial setting, and how's that trending, and is there a path to getting the combo data in the label or compendia, instead of running a large phase III study, for instance?

Michael Metzger
CEO, Syndax Pharmaceuticals

Maybe I'll start and then you. Yes, the answer to your first part of the question, which is, are you seeing off-label use? Almost half of our uses is off-label. Technically, what I mean by that is combinations, right? Most of our off-label use is in that way, and I'd say it's a very good sign for us, in the sense that most of the work is being done with VEN-AZA, right? I mean, most of the combination use is with VEN-AZA, and it also indicates that patients are being treated earlier. Physicians want to use the combinations as early as possible. They see the data, the real-world data supports that, and that's what's really happening. It's not on label, but really sets us up for success, is get patients to the highest rate of response, and then you can potentially transplant them after.

It's not just about monotherapy anymore. It's quickly becoming about combinations, and that's why it's so important for us to build up those data sets in real world and show what we can do in the frontline as well.

Paul Jeng
Analyst, Guggenheim

Okay.

Michael Metzger
CEO, Syndax Pharmaceuticals

Nick, and you had-

Nicholas Botwood
CMO, Syndax Pharmaceuticals

Then maybe the only other thing I would add, I think Michael's obviously right about the treatment of combinations. That is becoming a new standard of care in relapse/refractory, and we hope soon in the frontline as well, and that's very much on our minds. You asked about guidelines. That's always a consideration. Actually, across our programs, as and when we generate data that we think is clinically relevant, we would certainly submit it to the NCCN for consideration of guidelines, and more on that to come. The one other area I would highlight, which is again novel and where we're kind of pioneering the science, is something called MRD clearance in terms of treating in earlier lines, and we will present some data from the INTERCEPT study. This is a very important study. It's actually the first of its kind in the menin space.

Again, we'll have these data at ASH. This is a study led by Andrew Wei out of Australia, Melbourne, Australia, and essentially it looks at clearing MRD. So rather than treating at relapse, you actually intervene earlier. So when patients progress with evidence of MRD recurrence, you treat early, and we see very high rates of MRD eradication and reductions in MRD leading to an MRD response. And we think those data are going to be very important as well as we trend towards earlier lines of therapy, more combination use, and then more patients getting transplant, and then on to maintenance therapy after transplant. So it's a very exciting time, and we really are moving the field forwards and really want to continue to lead in that space.

Paul Jeng
Analyst, Guggenheim

All right. Then wanted to spend a minute or two on Niktimvo. Just first on the commercial performance, what percentage of the third line plus GVHD market have you sort of captured, and what are the next drivers for growth?

Michael Metzger
CEO, Syndax Pharmaceuticals

Right. The quarter was, again, another strong quarter of performance. New patient starts about 300, or actually more than 300, so growing nicely. Penetration into third line plus is more than a third, so we're feeling. Fourth line is more heavily penetrated. Third line is, I kind of classify it as third line plus, but we're doing very nicely against the competition. The data from the AGAVE trial was really very supportive of treating either before or after REZUROCK, which is the competitor in third line. I think the next step for the molecule is to expand into earlier line settings, which will be supported by some of the data we have coming up. We'll have data in the first quarter presented in a medical meeting in combination with ruxolitinib, with JAKAFI. This is potentially a steroid-sparing regimen, where we'll show the combination.

We'll have a control arm with JAKAFI alone and steroid alone. Looking at that and all the relevant endpoints, that'll be data that'll be available in the first quarter, and we think that's a very important first step on the way to treating newly diagnosed patients and really unlocking a very, what we think is a very large patient population, 15,000-17,000 patients in the newly diagnosed setting. Then the pivotal trial, which we're running versus steroids, that'll be data available in the first quarter of 2028. Again, a lot happening with Niktimvo as we continue to have great performance, and what really drives, it's not only new patient starts in the category, but it's how long they stay on, the duration, months if not years for these patients.

It's a long tail, and that's again, really important to how that business builds over time, but then expanding to new patient populations in the earlier line settings. That's, again, data that we'll have in the near term. Very exciting time for Niktimvo as well.

Paul Jeng
Analyst, Guggenheim

Yeah, that's right. For the phase II data, as you mentioned, coming up, assuming it's encouraging positive results, is there any opportunity to perhaps get it listed in compendia before that pivotal phase III reads out?

Michael Metzger
CEO, Syndax Pharmaceuticals

I think that you want to make a comment, Nick.

Nicholas Botwood
CMO, Syndax Pharmaceuticals

Yes, I think so. I think it's important for clinical practice. It's a study where we've already reported some tolerability data from an interim look and shown that the discontinuation rates on the combination of AXA/RUX is extremely low. Only one patient discontinued, so we're anticipating a very clean profile, as you'd expect from AXA. We're going to look at the response rate at six months, and I'm anticipating potentially both of the experimental arms in excess of what you'd expect with steroids alone, about a 40% response rate. As we have guided towards, we're going to present the data in the early part of 2027 because we think it's really important for that study to interpret the totality of the data. Makes sense not just at the response rate, but also the duration of response, event-free survival, and the tolerability.

Looking forward to having those data read out. We think they could be clinically relevant and certainly could inform guidelines ahead of the pivotal dexamethasone study reading out in early 2028. Both of the studies, I think, will inform clinical practice, but may also inform a future forward-looking clinical development plan. More on that to come.

Paul Jeng
Analyst, Guggenheim

All right, super. Don't want to forget about the early pipeline. You guys had an R&D Day earlier this year that sort of outlined a couple of really interesting assets. Maybe starting with the next generation menin inhibitor, what's the rationale for developing this molecule rather than Revuforj for myelofibrosis?

Michael Metzger
CEO, Syndax Pharmaceuticals

Right. So, I mean, I think it's, as it's stated, a next generation molecule. We've sort of picked the unique character, the next set of characteristics you'd want in a molecule in terms of potency, in terms of scheduling, in terms of the off-target effect, any kind of profile that you'd want in a next gen menin inhibitor, we kind of have in this next agent. I think myelofibrosis is a unique area. The science suggests that we can have a very broad disease-modifying opportunity there. So that, in a category where there's a lot of innovation going on, this is, I think, separate and apart from that. We will start with Revuforj because I think Revuforj gives us an opportunity to see whether the mechanism works as we think it will in this disease, and then switch to a next gen molecule.

Obviously, that gives us another clock in terms of IP coverage as well as there's different parts of the category in terms of pricing and crossing over indications is sometimes challenging. So I think we have a new opportunity, a de novo opportunity with a new molecule that we think sets up even better for us versus just using Revuforj, although we'll start with Revuforj.

Paul Jeng
Analyst, Guggenheim

Okay. Then lastly, you mentioned the allosteric EGFR inhibitor, which is branching out to lung cancer now as opposed to heme malignancies. So maybe just pretty broadly talk about the opportunity for this asset.

Michael Metzger
CEO, Syndax Pharmaceuticals

Yeah, I think simply stated, this is an area people know something about, right? This is an EGFR inhibitor specifically going after the L858R mutation, which is, for TAGRISSO, a problem, right? That's where 30%-40% of the mutations arise. Also, the atypical mutations is another area of focus for patients who fail TAGRISSO. So with an allosteric inhibitor, you're able to get at We're not going through the ATP binding site where all the competition seems to be. We are excluding exon 19 and exon 20. The drug doesn't work for those mutations. We're specifically focused on L858R and the other atypicals, which is a big, probably 30%, 40%-50% of the issue for TAGRISSO. So by not binding at the ATP binding site, you can actually double drug the target potentially with TAGRISSO.

You don't have to displace TAGRISSO, which is obviously a big and important product, but you can actually augment the use of TAGRISSO in these patients, and really, we'll start in relapse refractory disease, so where we're enrolling patients in the early phase I that have L858R mutations. I'd also say that this drug is designed to avoid the wild type, so you don't have the skin rash and issues like that, and it's very blood-brain penetrant. So the opportunity for patients who have brain metastases to be treated with this agent could be pretty important as well. It's an opportunity that we think pioneering new science in a way nobody else has an allosteric, nobody's taken one into the clinic. It's a new way of going after these difficult to treat diseases.

Paul Jeng
Analyst, Guggenheim

All right, super. I think with that, we're up on our time, so we'll wrap it there, but thank you, Michael and Nick, again for joining.